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Abstract
Here, we sought to determine whether peptide vaccines designed harbor both class I as well as class II restricted antigenic
motifs could concurrently induce CD4 and CD8 T cell activation against autologous tumor antigens. Based on our prior
genome-wide interrogation of human prostate cancer tissues to identify genes over-expressed in cancer and absent in the
periphery, we targeted SIM2 as a prototype autologous tumor antigen for these studies. Using humanized transgenic mice
we found that the 9aa HLA-A*0201 epitope, SIM2237–245, was effective at inducing an antigen specific response against
SIM2-expressing prostate cancer cell line, PC3. Immunization with a multi-epitope peptide harboring both MHC-I and MHC-
II restricted epitopes induced an IFN-c response in CD8 T cells to the HLA-A*0201-restricted SIM2237–245 epitope, and an IL-2
response by CD4 T cells to the SIM2240–254 epitope. This peptide was also effective at inducing CD8
+ T-cells that responded
specifically to SIM2-expressing tumor cells. Collectively, the data presented in this study suggest that a single peptide
containing multiple SIM2 epitopes can be used to induce both a CD4 and CD8 T cell response, providing a peptide-based
vaccine formulation for potential use in immunotherapy of various cancers.
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Introduction
Defined epitope vaccines elicit an immune response by
immunization with a synthetic fragment derived from the target
protein. This synthetic fragment is most commonly a 9–10aa long
peptide selected to bind human leukocyte antigen (HLA) class I. In
the case of cancer vaccines, epitopes that are restricted to a
particular MHC-I haplotype are designed and used to stimulate
the immune system against tumor-associated antigens (TAAs) [1].
In recent years, this approach for vaccine development has
delivered many immunogenic epitopes derived from known TAAs
[1–4]. With the advent of high throughput methodologies, the
TAA-derived immunogenic epitope portfolio has been significant-
ly enriched due to comprehensive profiling of TAAs of all cancer
types.
Peptide-based vaccines for cancer therapy have been developed
and subjected to preclinical and clinical testing in numerous
studies. Most notably, vaccination with the gp100-209:217(210M),
an HLA-A*0201-restricted epitope derived from the melanoma
antigen gp100, significantly improved the clinical response and
median overall survival of stage IV melanoma patients receiving
IL-2 therapy [2]. While peptide-based cancer vaccines had limited
success through the years, the survival benefit gained from the
gp100-209:217(210M) melanoma epitope vaccine trial was
received with much enthusiasm, and has reinvigorated interest
in peptide vaccines for cancer immunotherapy. Clinical trials in
numerous cancers including melanoma, mesothelioma, colorectal
and cervical cancer have been completed and shown this could be
an effective strategy for inducing a clinically beneficial immune
response against TAAs [1]. Recent studies suggest the inclusion of
multiple MHC class I restricted epitopes and addition of MHC
class II epitopes in a single longer peptide to improve vaccine
outcome [5–8]. Longer multi-epitope peptides targeting p53 have
been shown to induce a p53-specific CD4 and CD8 T-cell
response in early stage clinical trials against colorectal cancer [9].
Similarly, long peptide immunization against the mesothelioma
antigen WT1 induced antigen-specific, CD4 and CD8 T cell
response in 6 out of 9 patients [10]. Most impressively, a multi-
epitope vaccine against the Human Papillomavirus (HPV)
oncogenic E6 and E7 proteins to treat HPV-induced vulvar
intraepithelial neoplasia resulted in reduction in symptoms in 60%
of patients and complete clearance of disease in 25% of them [11].
These clinical findings support the idea that multi-epitope vaccines
can induce effective CD4 and CD8 anti-TAA responses resulting
in measurable clinical benefit.
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Using a genome-wide interrogation strategy to identify genes
that are expressed abundantly in human prostate cancer but
sparsely in non-cancerous adult tissues, we previously identified
numerous putative prostate TAAs including ETS related gene
(ERG) and Single-minded homolog 2 (SIM2) [3,4]. Additionally,
we have identified SIM2-derived, HLA-A*0201–restricted, immu-
nogenic epitopes with potential anti-cancer activity [3,12]. Here
we aimed to further investigate the immunogenicity of SIM2-
derived peptides using humanized mice and human prostate HLA-
A*0201-positive cell lines expressing this antigen. We also designed
and tested longer peptides harboring multiple MHC-I and MHC-
II-restricted epitopes to evaluate whether peptide vaccines that
deliver both class-I and class-II restricted epitopes could concur-
rently induce CD4 and CD8 T cell activation responsiveness in vivo
with a single peptide.
Methods
Mice and animal ethics statement
HHD mice were obtained from Dr. Francois Lemonnier (Unite
d’Immunite´ Cellulaire Antivirale, Institut Pasteur, Paris, France).
These mice are b2m2/2, Db2/2 double knockout and express
an HLA-A*0201 mono-chain composed of a chimeric heavy chain
(a1 and a2 domains of HLA-A*0201 allele and the a3 and
intracellular domains of Db allele) linked by its NH2 terminus to
the COOH terminus of the human b2m by a 15–amino acid
peptide arm [13]. All mice were housed in pathogen-free
conditions, and all experimental procedures involving animals
were approved by the Institutional Animal Care and Use
Committee at Beth Israel Deaconess Medical Center.
Cell line
T2 cells used in HLA-A*0201 binding assays and as targets in
ELISPOT assays were obtained from ATCC and cultured as
described in the accompanying product protocol. PC3 and
LNCaP lines were obtained from ATCC. PC3-A*0201+ cells
were produced by transfecting wild type PC3 cells with an HLA-
A*0201-puromycin containing retrovirus produced as described in
Maeurer et al [14]. The HLA-A*0201-containing plasmid was a
gift from Dr. Gordon Freeman at Dana Farber Cancer Institute.
In silico analysis of gene expression data
SIM2 gene expression data were obtained through the
Oncomine Research Edition (www.oncomine.org). The database
was queried for microarray datasets that show a 2-fold change in
SIM2 expression and a p value,.01 between cancer and control
groups.
Peptide design
The SIM2 protein sequence was downloaded from the NCBI
protein database (NP_005060.1). The IEDB (http://www.iedb.
org/) epitope prediction algorithm (Available at http://tools.
immuneepitope.org/main/html/tcell_tools.html) was then used to
predict regions of the protein that may bind MHC-I and MHC-II
molecules [15,16].
SIM2-derived peptide immunogenicity in transgenic
mice
Eight- to 12-wk-old male HHD mice were injected sub-
cutaneously on the right flank with 100 mg of each candidate
peptide emulsified in 50 mL of incomplete Freund’s adjuvant and
50 mL PBS in the presence of 150 mg of the I-Ab–restricted
HBVcore128–140 T helper epitope (TPPAYRPPNAPIL) [17] or the
SIM2 derived I-Ab epitope, LKLIFLDSRVTEVTG. Mice
immunized with the long SIM2 peptide received 150 ug total
under the same conditions. Ten to 12 d after immunization,
spleens were harvested and splenocytes were tested for peptide-
induced specific release of IFN-c by enzyme-linked immunospot
(ELISPOT) assay.
ELISPOT assay
ELISPOT was performed as described by the manufacturer’s
instruction. Briefly, 96-well Millipore Immobilon-P plates were
coated with 100 mL/well mouse IFN-c specific capture mAb
(AN18; Mabtech, Inc.) at a concentration of 10 mg/mL in PBS
overnight at 4uC. To investigate the recall response to immuni-
zation with various peptides, a total of 2.56105 splenocytes were
seeded in each well in four replicates, and 2.56105 peptide-loaded
(10 mg peptide/mL, for 2 h at 37uC) splenocytes pretreated with
50 mg/mL mitomycin C for 1 h were added to each well. To
investigate the response of immunized mice to prostate cancer cell
lines, 56104 splenocytes isolated from immunized mice were
cultured with 56104 tumor cells pretreated with 50 mg/ml of
mitomycin C for 1 h. ELISPOT was developed as described in
manufacturer’s instruction (Mabtech, Murine IFN-c ELISPOT
kit). Spots measured in these experiments were multiplied by the
appropriate dilution factor to express IFN-c producing cells per
million splenocytes.
To measure the IL-2 response of CD4 T-cells, pure CD4+ T-
cells were isolated using the EasySep mouse CD4 T-cell
enrichment kit from StemCell Technologies (Cat: 19752). IL-2
ELISPOT was performed as described by the manufacturer’s
instruction (eBioscience; 88-7824). CD4+ cells were co-cultured
with splenocytes loaded with various peptides (10 mg peptide/mL,
for 2 h at 37uC) and treated with 50 mg/mL mitomycin C for 1 hr.
ELISPOT plates were developed after 24 hours.
Intracellular flow cytometry
Splenocytes were isolated from immunized HHD mice and co-
cultured at a 1:1 ratio with T2 cells loaded with 10 mg of peptide/
mL, for 2 h at 37uC. Cells were incubated overnight with
Brefeldin A. Cells were stained for surface antigens and then
permeabilized using eBioscience permeabilization buffers
(eBioscience; 88-8824-00), and then stained intracellularly for
IFN-c. Cells was analyzed with a BeckmanCoulter Galios flow
cytometer.
Statistical analysis
Statistical analysis was performed using the Student’s T-test. P
values of less than 0.05 were considered significant and are
denoted by an asterisk in figures.
Results
SIM2 is overexpressed in various cancers
Previously, we reported that SIM2 was an ideal target for
prostate cancer immunotherapy, being a protein overexpressed in
prostate cancer with little expression in peripheral tissue [3]. To
further investigate the suitability of this gene as a target for
immunotherapy, we used the Oncomine database to examine the
expression of SIM2 in other cancers (Figure 1A). Our initial
findings in prostate cancer were replicated in other prostate cancer
datasets within the Oncomine database (Figure 1B). Additionally,
we found that many other cancers overexpressed SIM2. In
particular, colon cancer had more than a 4-fold increase
(Figure 1C) in SIM2 expression, and breast cancer had more
than a 2-fold increase (Figure 1E). Significant increases were also
Peptide Vaccination against the Tumour Antigen SIM2
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found in pancreatic cancer and oligodendroglioma (Figure 1D
and 1F). Together, these data indicate that SIM2 is an attractive
immunotherapeutic target for a wide range of cancers.
SIM2237 is naturally processed and presented on HLA-
A*0201 in prostate cancer cells
Previously, we had identified a number of 9aa long immuno-
genic HLA-A*0201-restricted epitopes derived from SIM2 [3]. To
determine if any of these immunogenic peptides were processed
and presented by human prostate cancer cells expressing SIM2,
we investigated the activity of splenocytes from HLA-A*0201
transgenic HHD mice immunized with the SIM2205 (YQIVGL-
VAV), SIM2237 (SLDLKLIFL), SIM2241 (KLIFLDSRV), or
control peptide against PC3 and LNCaP cells stably expressing
HLA-A*0201. From our previous work, we have identified SIM2
expression in PC3 cells but not LNCaP cells [12]. We found that a
significantly increased number of splenocytes isolated from
SIM2237 produced IFN-c (198/10
5 cells) in response to PC3-
A2.1 cells compared to control mice (55/105 cells), indicating that
SIM2-expressing cells process and present this epitope
(Figure 2A). In contrast, splenocytes from SIM2241 and
SIM2205 immunized mice had no increased activity against the
PC3 cells compared to control immunized mice. Additionally,
splenocytes from all SIM2 immunized mice had no increased
response against PC3 cells that did not express HLA-A*0201,
indicating that this effect was dependent on the MHC-I complex.
Splenocyte activity of SIM2 peptide immunized mice was also
tested against LNCaP cells, a cell line that does not express SIM2.
Splenocytes from all SIM2-immunized mice had no increased
activity against these cells compared to controls (Figure 2B).
These data suggest that SIM2237 is the immune-dominant epitope
in an HLA-A*0201 restricted setting and could be a potential
epitope to target prostate cancer.
In silico design and validation of a multi-epitope vaccine
containing the prostate cancer epitope SIM2237
While immunization with SIM2237 generated an antigen
specific response against tumor cells, the immunization regimen
required the addition of an HBV-derived I-Ab-restricted epitope
(HBV128) to induce this response. While providing CD4 stimula-
tion using an HBV-derived peptide is efficient, it does not generate
tumor antigen specific CD4 cells. Because CD4 T cells can directly
kill tumor cells, expanding cells specific for the target tumor
antigen may be beneficial. To eliminate the need of the HBV
Figure 1. Human SIM2 gene expression analysis in various cancers. SIM2 gene expression data were extracted from the Oncomine Research
Edition. Microarray datasets that show a 2-fold change in SIM2 expression between cancer and control groups and a p value,0.01 are highlighted.
(A) Comparison of SIM2 gene expression between cancer and control specimens. Red color indicates SIM2 overexpression and the blue color
indicates SIM2 down-regulation in cancer. Numbers in the boxes indicate the number of datasets showing statistical significance. Box plots were
obtained from the datasets selected in (A) to highlight significant overexpression of SIM2 in Prostate Carcinoma (1. Prostate Gland (n = 23), 2. Prostate
Carcinoma (n = 65); P= 2.41610214, [40]) (B); Colon Carcinoma (1. Colon (n = 10), 2. Colon Carcinoma (n = 5); P = 1.65610212 [41]). (C); Breast
Carcinoma (1. Breast (n = 4), 2. Invasive Breast Carcinoma (n = 154); P = 2.2561024, [42]) (D); Oligodendroglioma (1. Brain (n = 23), 2.
Oligodendroglioma (n = 50); P = 3.3161029 [43]) (E); and Pancreatic Carcinoma (1. Pancreas (n = 16), 2. Pancreatic Carcinoma (n = 36);
P = 3.0161027 [44]) (F).
doi:10.1371/journal.pone.0093231.g001
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helper peptide, we hypothesized that CD4 and CD8 T-cells could
be stimulated by a single peptide derived from SIM2 containing
both MHC-I and MHC-II binding epitopes. To design this multi-
epitope long peptide, we extended the amino acids around the
SIM2237 core and used prediction algorithms to determine if the
longer peptides had MHC-II binding potential. Following this
approach, we found that this peptide was predicted to bind many
human MHC-II molecules (Table 1). This peptide also included
an I-Ab-restricted epitope, allowing us to test whether the long
SIM2 peptide could induce a SIM2237 response in the HHD mice.
To determine the in vivo immunogenicity of the longer peptide, we
immunized HHD mice with the SIM2237 CD8 epitope and CD4
HBV helper peptide or the long peptide containing both the
MHC-I and MHC-II peptide (Figure 3A). Mice immunized with
SIM2237 peptide alone had no significant recall response to the
peptide. In contrast, mice immunized with both SIM2237 and
HBV128 had a significantly increased IFN-c recall response to the
SIM2237 antigen. We found that replacing the HBV128 peptide
with the SIM2 derived MHC-II, SIM2240–254 (LKLIFLDSRV-
TEVTG) still generated a recall response to the SIM2237 epitope.
Similarly, when mice were immunized with SIM2230–256
(NMFMFRASLDLKLIFLDSRVTEVTGYE) containing both
MHC-I and MHC-II epitopes, a significant CD8 recall response
to the SIM2237 epitope was elicited. Intracellular flow cytometry
for IFN-c confirmed these findings, showing that splenocytes from
mice immunized with either the SIM2237+HBV128 combination,
SIM2237+SIM2240–254 combination or the longer SIM2230–256
peptide all generated a significant IFN-c recall response to the
SIM2237 epitope (p,0.05) (Figure 4). Additionally, the IL-2
response of CD4 cells to the helper peptides was measured by
ELISPOT. Mice immunized with the HBV128 generated a
significantly greater recall response to HBV128 compared to
controls. Similarly, mice immunized with SIM2240–254 or
SIM2230–256 generated a significantly greater IL-2 response to
the MHC-II-restricted SIM2240–254 epitope compared to controls.
These data support our hypothesis that the longer SIM2230–256
peptide could simultaneously generate both a CD4 IL-2 response
against the SIM2240–254 epitope, as well as an IFN-c response
against the SIM2237 epitope.
The multi-epitope SIM2230–256 peptide induces an
antigen-specific response against human SIM2-
expressing prostate cancer cell lines
We further tested the effectiveness of the SIM2230–256 peptide
by measuring the IFN-c recall response against SIM2-expressing
prostate cancer cells. HHD mice were immunized with either the
long peptide or HBV128. Splenocytes were co-cultured with PC3
or PC3-A2.1 cells and recall activity was measured by IFN-c
ELISPOT. Splenocytes isolated from mice immunized with the
long-SIM2 peptide had significantly increased activity against
PC3-A2.1 cells. Additionally, the number of splenocytes isolated
from long-SIM2 immunized mice responding to the PC3-A2.1
cells was significantly higher than those responding to the PC3-
WT cell line, indicating that this recall response was dependent on
expression of HLA-A*0201 (Figure 5A). Cells from SIM2230–256-
Figure 2. T-cells isolated from SIM2 immunized mice respond
to human Prostate Cancer cell lines expressing ERG. Reactivity of
splenocytes from SIM2 peptide immunized mice against human
prostate cancer cell lines PC3 (A) and LNCaP (B). Splenocytes from
HHD mice immunized with HBV and various SIM2-derived peptides or
HBV alone were co-cultured with PC3 or LNCaP. Production of IFN-c by
splenocytes in response to these tumor cell lines was assessed by
ELISPOT. Figures show mean 6 standard deviation of 3 mice from one
experiment. The effect of splenocytes from SIM2-immunized mice
against the cell lines was repeated in 2 separate experiments.
doi:10.1371/journal.pone.0093231.g002
Figure 3. SIM2230–256 induces an IFN-c and CD4 IL-2 response.
IFN-c production by splenocytes in mice immunized with various
treatments. Mice were immunized with either the 9aa SIM2237 epitope
combined with HBV or SIM2240–254, or the SIM2230–256 peptide alone.
IFN-c production was measured by ELISPOT. IL-2 production by CD4 T-
cells. CD4 T-cells were sorted from the spleens of immunized mice and
tested for reactivity to HBV128 and SIM2240–254 by IL-2 ELISPOT.
doi:10.1371/journal.pone.0093231.g003
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immunized mice were also tested for activity against the SIM2
negative cell line LNCaP. No increased IFN-c response was
detected against this cell line (Figure 5B). Together these data
suggest that a single peptide containing both MHC-I and MHC-II
epitopes derived from SIM2 can induce T-cell activity against
SIM2-expressing prostate cancer cells.
Discussion
Peptide vaccines have been traditionally designed to elicit CTL
responses against tumor antigens [18–21] resulting in some, but
limited clinical benefit, mainly due to the transience and low
magnitude of the immune responses they induce [22]. However,
recent evidence suggests the importance of CD4 T helper cells in
the anti-tumor immune process [23–25]. The contribution of CD4
T cells to antigen-specific immunity is well appreciated in
mounting immune responses to pathogens, a well-orchestrated
process whereby both class I and class II MHC-mediated epitope
presentation takes place [26]. Activated CD4 T cells secrete many
cytokines that stimulate dendritic cells, leading to enhanced
antigen presentation and potentiated anti-tumor immunity
[27,28]. In addition, CD4 T cell-mediated responses are suspected
to contribute to the establishment of memory responses [29]. CD4
cells have also been found to develop cytotoxic activity and be able
to eradicate melanoma tumors in lymphopenic hosts [30].
Collectively, these findings provide rationale for induction of
Figure 4. IFN-c production by CD8 T-cells from SIM2-immunized mice. Mice were immunized with either SIM2237, SIM2237+HBV128,
SIM2237+SIM2240–254 or SIM2230–256. Splenocytes were harvested and incubated overnight with T2 cells loaded with the SIM2237 peptide. IFN-c was
measured by flow cytometry. FACS plots show the median IFN-c production for each group (A) and replicate data obtained from each group (B).
doi:10.1371/journal.pone.0093231.g004
Table 1. Human MHC-II-restricted epitopes predicted from the SIM2 long peptide using IEDB tool.
Allele Sequence Percentile Ranka Comb.Lib. IC50(nM)b
HLA-DRB1*07:01 MFMFRASLDLKLIFL 0.31 57.04
HLA-DPA1*02:01/DPB1*01:01 MFMFRASLDLKLIFL 0.92 7
HLA-DRB1*09:01 MFMFRASLDLKLIFL 1.78 1.18
HLA-DPA1*02:01/DPB1*05:01 FMFRASLDLKLIFLD 1.83 0.19
HLA-DRB4*01:01 LDLKLIFLDSRVTEV 1.98 130.98
HLA-DPA1*03:01/DPB1*04:02 MFMFRASLDLKLIFL 2.08 3.31
HLA-DPA1*01/DPB1*04:01 NMFMFRASLDLKLIF 3.22 138.55
HLA-DQA1*01:01/DQB1*05:01 MFMFRASLDLKLIFL 3.91 0.48
HLA-DPA1*01:03/DPB1*02:01 NMFMFRASLDLKLIF 4.69 0.72
HLA-DRB3*01:01 NMFMFRASLDLKLIF 5.31 113.08
HLA-DRB1*01:01 LKLIFLDSRVTEVTG 7.88 0.67
HLA-DQA1*04:01/DQB1*04:02 MFRASLDLKLIFLDS 9.51 190.23
HLA-DQA1*05:01/DQB1*02:01 NMFMFRASLDLKLIF 11.5 2.95
HLA-DQA1*03:01/DQB1*03:02 RASLDLKLIFLDSRV 15.99 58.07
Only the top epitopes having the lowest percentile score and lowest IC50 are selected. One epitope is shown for each HLA allele out of 137 predicted binders.
aPercentile Rank – Percentage of all peptides binding with this efficacy or lower.
bCombLib IC40 – Predicted peptide concentration required to bind 50% of MHC molecules.
doi:10.1371/journal.pone.0093231.t001
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CD4 T cell responses with cancer vaccines, either alone, or in
combination with MHC-I-restricted epitopes.
We and others have previously demonstrated overexpression
and specificity of SIM2 in prostate cancer patients [31,3,12].
Additionally, we have identified SIM2-derived, HLA-A2.1-re-
stricted epitopes that exhibit the ability to break immune tolerance
to SIM2 in mice, and identified SIM2-specific auto-antibodies in
sera from patients with PCa [3]. Our work has subsequently
suggested a biological role for SIM2 in PCa [12]. However, we
have not determined whether the HLA-A2.1-restricted epitopes
we identified are naturally processed and presented in tumor cells,
nor have we identified longer epitopes that could also trigger CD4
T cell responses. In the present work, we show that overexpression
of SIM2 is not limited to PCa. SIM2 is similarly overexpressed in
several other malignancies, including colon cancer, breast cancer,
cervical cancer, pancreatic cancer and oligodendroglioma, sug-
gesting SIM2 may be an attractive target for immunotherapy of a
wide range of cancers. Interestingly, while an overexpression of
SIM2 in cancer might suggest a tumorigenic role for SIM2, its
frequent down-regulation in other cancers such as oesophageal,
kidney, and head and neck cancers (Figure 1) might suggest a
tumor suppressive role. In fact, SIM2 has been shown to suppress
breast cancer growth and invasion in a xenograft model [32].
More intriguing is the observation that Down’s syndrome patients
are prone to acute leukemia, including acute lymphoblastic
leukemia (ALL), while solid tumors, especially breast cancer, is
rare [33]. SIM2 is among many transcription factors encoded by
genes located on the human chromosome 21. Together, these
studies suggest that SIM2 is an attractive immunotherapeutic
target for a range of different cancers.
Our data showed that a SIM2237-specific response could be
elicited against the SIM2-expressing PC3, but not against the
SIM2 negative LNCaP cell line (Figure 2). However, SIM2241
and SIM2205 could not induce a CTL response against these same
cells, despite both of these peptides showing antigen-specific CTL
responses in HLA-A*0201 transgenic mice [3]. In this study we
were unable to test the response to another SIM2 expressing
prostate cancer cell line, VCaP, due to the cell lines failure to grow
after transfection with HLA-A0201. However, The findings that
not all immunogenic peptides generate a response against SIM2
expressing cell lines supports the notion that peptide presentation
is more complex than MHC-I-binding affinity and that numerous
factors contribute to peptide presentation including affinity for the
TAP molecule and cytosolic half-life [34,35]. Nonetheless,
together these data indicate that the SIM2237 peptide is presented
in an HLA-A*0201-restricted manner on cells expressing the
SIM2 molecule.
Algorithms that predict MHC-II-restricted epitopes indicate
that all proteins, native and mutated, harbor multiple potential
MHC-II-restricted epitopes. Compared to MHC-I epitopes,
MHC-II-restricted epitopes exhibit a much wider specificity and
cross-reactivity, as exemplified by the ability of the PADRE (Pan
DR epitope) peptides to recognize a high number of MHC-II
alleles in both human and mouse [36]. In the case of SIM2
protein, it is clear many of the epitopes we predicted to bind HLA-
DR/DP/DQ would target large populations of patients because of
their wide specificity. However, while targeted clinical use of these
epitopes would necessitate HLA typing of patients, our mouse
immunogenicity tests suggest the long SIM2 peptide harbors an
IA-b-restricted epitope(s), as evidenced but the ability of the long
peptide to elicit a SIM2237-specific CTL response in the absence of
the HBV128 helper peptide. This response is equal in magnitude to
that induced with the combination of HLA-A2.1-restricted
SIM2237 and the I-Ab-restricted HBV128 epitopes. Because long
peptides are internalized and processed by dendritic cells, our
results indicate a successful internalization and processing of the
long peptide and an optimal presentation in the context of both
MHC-I and MHC-II complexes to T lymphocytes. The ability of
dendritic cells to successfully achieve these steps implies cancer
vaccines could be made that contain one single peptide, thus
dramatically reducing the cost and regulatory procedures on the
path to clinical application. Previous studies have elegantly
demonstrated that an increase in the length of the peptide used
for vaccination strongly affects the magnitude of the induced CTL
response [6,37]. Comparative experiments showed vaccination
with long peptides containing a CTL epitope outperformed
vaccination with the CTL peptide alone at inducing effective anti-
tumor CTL responses [38]. The low effectiveness of CTL epitopes
was shown to be due to the transient nature of the response they
can elicit and their failure to induce CTL memory [39].
Together the findings of this study suggest prostate tumor cells
expressing SIM2 present the SIM2237 epitope in an HLA-A*0201-
dependent fashion. Additionally, the multi-epitope peptide
SIM2230–256 can provide TCR stimulation to both CD4 T cells
and CD8 T cells simultaneously. Furthermore, this peptide
contains numerous epitopes predicted to bind to various human
MHC-II molecules, suggesting that this peptide could induce a
CD4 T-cell response in individuals with many different HLA-DR/
DP/DQ alleles. Collectively, these data indicate that an effective
Figure 5. Splenocytes from SIM2230–256-immunized mice re-
sponse to PC3-A2.1 cells. Splenocytes from HHD mice immunized
with HBV and various SIM2230–256 peptides or HBV alone were co-
cultured with PC3, PC3-A2.1 (A) or LNCaP (B). Production of IFN-c by
splenocytes in response to these tumor cell lines was assessed by
ELISPOT. Data is representative of 2 experiments and shows mean 6
standard deviation.
doi:10.1371/journal.pone.0093231.g005
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antigen-specific response can be augmented by concurrent
inclusion of class-I and class-II restricted epitopes in peptide
vaccine formulations targeting autologous human tumor antigens.
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